Hørsholm,
Previously reported results from the trial showed that vaccination with 100ug ABNCoV2 in 103 seropositive subjects was able to demonstrate a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the
For the follow-up analysis, 41 subjects were followed for six months post vaccination. From this group, two subjects with confirmed COVID-19 disease were excluded from the immune analysis. Six months post vaccination, neutralization titers were six times higher than pre-boost titers against
CEO
"These exciting follow-up results from the Phase II clinical trial confirm that the ABNCoV2 delivers a strong booster result also six months after vaccination for all variants of concern, including Omicron, without modification to the vaccine. This is great news that supports the use of ABNCoV2 as a universal booster vaccine. We look forward to seeing the results from the ongoing clinical Phase III trial, with sites opening up in
Additional information on the follow-up result from the Phase II clinical trial can be found in the press release published today by
https://www.bavarian-nordic.com/investor/news/news.aspx?news=6650
About the cVLP COVID-19 vaccine product, ABNCoV2
Under the PREVENT-NCoV consortium, ExpreS2ion and its 34%-owned associate company AdaptVac have applied their unique Drosophila S2 insect cell protein production technology, ExpreS2(TM), and capsid virus-like particle (VLP) COVID-19 technology, respectively, to develop a novel next-generation COVID-19 vaccine, known as ABNCoV2.
ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing durable and highly protective response from a COVID-19 challenge. Initial Phase I/II clinical study data from COUGH-1, the first-in-human trial of the vaccine, have confirmed its ability to induce strong and broad antibody levels, superior to those of the current approved vaccines, while also providing a favorable safety profile. In the Phase II trial, ABNCoV2 was demonstrated to induce a significant boost to the neutralizing antibodies against all tested variants, including the Omicron variant.
Certified Adviser
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion
https://news.cision.com/expres2ion-biotechnologies/r/durable-antibody-response-reported-for-the-abncov2-covid-19-vaccine-six-months-after-vaccination-in-,c3649260
https://mb.cision.com/Main/14402/3649260/1639488.pdf
(c) 2022 Cision. All rights reserved., source